

APPENDIX

EXHIBITS PROVIDED FOR THE HEARING RECORD BY THE SUBCOMMITTEE ON MONOPOLY

[From the Journal of the American Medical Association]

REPORT OF THE COMMITTEE FOR THE ASSESSMENT OF BIOMETRIC ASPECTS OF CONTROLLED TRIALS OF HYPOLYCEMIC AGENTS

- Sec.
- 1. Introduction.
- 2. Clinical trials in general.
- 3. UGDP trial.
- 3.1 Methods.
- 3.1.1 The selection of patients.
- 3.1.2 Randomization and allocation of treatments.
- 3.1.3 Data collection.
- 3.1.4 Methods of data analysis.
- 3.2 Findings.
- 4. Other studies of hypoglycemic agents.
- 4.1 Keen et al (The Bedford study).
- 4.2 Paasikivi.
- 4.3 Feldman et al
- 4.4 Tzargournis and Reynerston.
- 4.5 Summary
- 5. Criticisms of the trials of oral hypoglycemic agents.
- 5.1 Main issue in criticisms of the UGDP trial.
- 5.2 Selection of patients.
- 5.3 The UGDP mortality findings.
- 5.4 Failure to adapt dosage of drugs to individual need.
- 5.5 Discontinuation of tolbutamide and phenformin in UGDP study.
- 6. Data from the UGDP and Bedford trials.
- 6.1 UGDP data.
- 6.1.1 Randomization by ser within clinics.
- 6.1.2 Cardiovascular failure rates.
- 6.1.3 Multiple logistic model.
- 6.1.4 Analysis with respect to adherence to assigned treatment.
- 6.1.4.1 The extent of the problem.
- 6.1.4.2 Statistical analysis.
- 6.2 The Bedford trial.
- 6.2.1 Cardiovascular events.
- 6.2.2 Mortality data.
- 6.2.2.1 Failure rates and death rates.
- 6.2.2.2 Multiple logistic model.
- 7. Conclusions.
- 7.1 Protocol.
- 7.2 Conduct of the study.
- 7.3 Methods of analysis.
- 7.4 Findings.
- References.
- Appendix A Use of the logistic model.
- Appendix B Relative allocation method.
- Appendix C Survival modeling method.
- Tables.